Healthcare

Cochlear Limited (ASX:COH) is a global medical technology company focused on implantable hearing solutions. The company designs, manufactures and supports devices that help people with severe hearing loss access sound. This article examines Cochlear’s healthcare technology business, its market position and the factors that …

CSL Limited (ASX:CSL) is a global biotechnology company focused on developing and manufacturing medicines that address serious health conditions. The company operates across plasma-derived therapies, vaccines and specialty pharmaceutical products. This article examines CSL’sBusinessmodel, global operations and the factors shaping its future healthcare strategy.

Imugene Limited (ASX:IMU) is an Australian biotechnology company focused on developing immunotherapies designed to support cancer treatment. The company’s programs are based on approaches that aim to harness the body’s immune system to identify and attack cancer cells. This article examines Imugene’s technology focus, …

Neuren also lodged a technical ASX update (Appendix 3A.1) on 18 September 2026 clarifying that securityholders with a registered address in New Zealand who make no directCreditelection will now have theirInterim Dividendwithheld in NZD rather than AUD. While largely administrative, this update landed alongside …

Mesoblast Limited (ASX:MSB) is a biotechnology company focused on developing cell-based medicines for serious medical conditions. The company’s research approach involves specialised cell therapies designed to address areas where existing treatmentOptionsmay be limited. This article examines Mesoblast’s technology platform, clinical development activities and the …

Clarity Pharmaceuticals Limited (ASX:CU6) is an Australian clinical-stage biotechnology company focused on radiopharmaceuticals for cancer diagnosis and treatment. The company is developing targeted therapies and imaging products based on radioactive compounds designed to identify and address cancer cells. This article examines Clarity’s technology focus, …

The FY26 results, combined with continued positive news flow on academic medical centre adoption, outpatient network rollout and expanding regulatory approvals for CT:VQ™, appear to have driven sustained buying interest into 18 September 2026, culminating in the day's double-digit percentage gain.